Minimally invasive, Indocyanine-Guided Metastasectomy in patients with Colorectal Liver Metastases

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON21326

Enrollment

186

Registered

2019-04-09

Start date

2018-09-01

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colorectal liver metastases

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: 18 years or older Patients with colorectal liver metastases (primary and recurrent CRLM) planned for curative-intent minimally invasive surgery, either laparoscopic or robotic resection Patients eligible for indocyanine infusion 24h prior to surgery according to the hospitals protocol Patients with or without neoadjuvant chemotherapy (for primary and/or secondary colorectal tumor/metastases)

Exclusion criteria

Exclusion criteria: Patients with contraindications for Indocyanine green: o Iodide allergy of allergies for shells and/or clamps o Impaired kidney function (eGRF <50) Local recurrent CRLM at the site of previous ablative therapy

Design outcomes

Primary

Measure	Time frame
Percentage radical resections	—

Secondary

Measure	Time frame
Incremental diagnostic accuracy of NIRF imaging The impact of fluorescent guided resections on surgical patient parameters (eg. Blood loss, operation time) The short-term (<6 months) oncological outcomes and intrahepatic recurrence rates, with an emphasis on local recurrence at the site of resection. These outcomes will be compared with the Dutch Hepato Biliary Audit (DHBA) data. Long-term oncological outcomes: overall survival, disease free survival	—

Measure

Time frame

Incremental diagnostic accuracy of NIRF imaging The impact of fluorescent guided resections on surgical patient parameters (eg. Blood loss, operation time) The short-term (<6 months) oncological outcomes and intrahepatic recurrence rates, with an emphasis on local recurrence at the site of resection. These outcomes will be compared with the Dutch Hepato Biliary Audit (DHBA) data. Long-term oncological outcomes: overall survival, disease free survival

—

Contacts

Public ContactBabs Sibinga Mulder

Leids Universitair Medisch Centrum

b.g.sibinga_mulder@lumc.nl0715265401

Outcome results